Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium

Susan E. Dorman, Stefan Goldberg, Jason E. Stout, Grace Muzanyi, John L. Johnson, Marc Weiner, Lorna Bozeman, Charles M. Heilig, Pei Jean Feng, Ruth Moro, Masahiro Narita, Payam Nahid, Susan Ray, Edward Bates, Betial Haile, Eric L. Nuermberger, Andrew Vernon, Neil W. Schluger

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Background.Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment.Methods.In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase.Results.Negative cultures on solid media occurred in 145 of 174 participants (83.3) in the rifampin group and 171 of 198 participants (86.4) in the rifapentine group (difference, 3.0; 95 confidence interval [CI]: - 4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1) in the rifampin group and 133 of 196 (67.9) in the rifapentine group (difference, 2.8; 95 CI: -6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7) in the rifampin group and 40 of 275 participants (14.5) in the rifapentine group prematurely discontinued treatment (P =. 79).Conclusions.The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted.

Original languageEnglish (US)
Pages (from-to)1030-1040
Number of pages11
JournalJournal of Infectious Diseases
Volume206
Issue number7
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium'. Together they form a unique fingerprint.

Cite this